Cargando…
Recent Developments of Circulating Tumor Cell Analysis for Monitoring Cutaneous Melanoma Patients
SIMPLE SUMMARY: Circulating tumor cells (CTCs) originating from cutaneous melanoma patients have been studied for several decades as surrogates for real-time clinical status and disease outcomes. Here, we will review clinical studies from the last 15 years that assessed CTCs and disease outcomes for...
Autores principales: | Shoji, Yoshiaki, Bustos, Matias A., Gross, Rebecca, Hoon, Dave S. B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870206/ https://www.ncbi.nlm.nih.gov/pubmed/35205608 http://dx.doi.org/10.3390/cancers14040859 |
Ejemplares similares
-
Integrated Assessment of Circulating Cell-Free MicroRNA Signatures in Plasma of Patients with Melanoma Brain Metastasis
por: Bustos, Matias A., et al.
Publicado: (2020) -
A Pilot Study Comparing the Efficacy of Lactate Dehydrogenase Levels Versus Circulating Cell-Free microRNAs in Monitoring Responses to Checkpoint Inhibitor Immunotherapy in Metastatic Melanoma Patients
por: Bustos, Matias A., et al.
Publicado: (2020) -
Acetylated DNMT1 Downregulation and Related Regulatory Factors Influence Metastatic Melanoma Patients Survival
por: Zhang, Xiaoqing, et al.
Publicado: (2021) -
Methylated circulating tumor DNA as a biomarker in cutaneous melanoma
por: Diefenbach, Russell J, et al.
Publicado: (2020) -
Interleukin enhancer‐binding factor 2 promotes cell proliferation and DNA damage response in metastatic melanoma
por: Zhang, Xiaoqing, et al.
Publicado: (2021)